Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates

By Zacks Investment ResearchStock MarketsJul 27, 2021 08:07AM ET
www.investing.com/analysis/perkinelmer-pki-q2-earnings-and-revenues-surpass-estimates-200593895
PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates
By Zacks Investment Research   |  Jul 27, 2021 08:07AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

PerkinElmer (NYSE:PKI), Inc. PKI reported second-quarter 2021 adjusted earnings per share (EPS) of $2.83, which beat the Zacks Consensus Estimate of $2.41 per share by 17.4%. The bottom line improved 80.2% from the year-ago quarter.

GAAP EPS in the quarter was $2.19, compared with the year-ago quarter’s figure of $1.23.

Revenue Details

Based in Waltham, MA, this leading MedTech company reported revenues of $1.23 billion, up 51.3% from the year-ago quarter and 41% organically. Adjusted revenues in the reported quarter were $1.23 billion, up 51.4% year over year. The top line surpassed the Zacks Consensus Estimate by 9.8%.

Segment Details

Discover & Analytics Solutions

At this segment, revenues were $513 million, reflecting a rise of 31.2% from the year-ago quarter. Organically, the segment saw an increase of 22% in the quarter under review.

Coming to profits at the DAS segment, the company reported second-quarter 2021 adjusted operating income of $101 million, up 77.2% from the year-ago quarter.

Diagnostics segment

Revenues at this segment amounted to $716 million, up 70.1% on a year-over-year basis. Organically, the segment increased 59% in the second quarter.

Adjusted operating income in the segment totaled $328 million, compared with $190 million in the year-ago quarter.

Margin Analysis

Adjusted gross profit in the quarter amounted to $711.2 million, up 53.3% year over year. Adjusted gross margin, as a percentage of revenues was 57.8%, up 70 basis points (bps) year over year.

Selling, general and administrative expenses were $281.8 million, up 27.5% on a year-over-year basis. Research and development expenses amounted to $65.8 million, up 32.9% from the year-ago quarter.

Adjusted operating income was $411.3 million, which soared 80.2% from the year-ago quarter. Adjusted operating margin, as a percentage of revenues was 33.5%, up 540 bps.

Financial Update

The company exited the second quarter with cash and cash equivalents of $572.8 million, compared with $988.2 million in the prior quarter.

Cumulative net cash provided by operating activities for the second quarter totaled $761.4 million, compared with $198.5 million in the year-ago period.

2021 Guidance

PerkinElmer has provided guidance for third-quarter 2021 and raised full-year 2021 outlook.

For third-quarter 2021, the company projects adjusted EPS of $1.62. The Zacks Consensus Estimate is pegged at $1.70 per share. For the same period, revenues are anticipated to be around $1 billion. The Zacks Consensus Estimate for the same stands at $951.6 million.

For 2021, the company expects adjusted EPS to be $9.88 (up from the previous estimate of at least $9.40). The Zacks Consensus Estimate is pegged at $9.50 per share.
Revenues are anticipated to be $4.57 billion (up from the prior estimate of at least $4.37 billion). The consensus mark stands at $4.37 billion.

Conclusion

PerkinElmer exited the second quarter on a strong note, wherein both earnings and revenues beat their respective consensus mark. The company witnessed robust core segmental performance in the quarter under review. Expansion in both gross and operating margins instills optimism.

Interestingly, the company inked a deal to acquire BioLegend — a leading manufacturer of innovative antibodies and research agents — for an amount of $5.25 billion. Per management, the company exhibited encouraging performance throughout the first half of 2021 and is well-positioned to execute on both its short and long-term goals.

However, PerkinElmer continues to make acquisitions, which increases integration risks.

Zacks Rank

Currently, PerkinElmer carries a Zacks Rank #3 (Hold).

Key Picks

Some better-ranked stocks, which are expected to report earnings soon, are AMN Healthcare Services (NYSE:AMN) Inc. AMN, Catalent (NYSE:CTLT), Inc. CTLT and Encompass Health (NYSE:EHC) Corporation EHC.

The Zacks Consensus Estimate for AMN Healthcare’s second-quarter 2021 adjusted EPS is currently pegged at $1.47. The consensus mark for second-quarter revenues stands at $829.4 million. The company currently carries a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Catalent currently sports a Zacks Rank #1. The Zacks Consensus Estimate for Catalent’s fourth-quarter fiscal 2021 adjusted EPS is currently pegged at $1.04. The consensus mark for fiscal fourth-quarter revenues stands at $1.13 billion.

The Zacks Consensus Estimate for Encompass Health’s second-quarter 2021 adjusted EPS is currently pegged at $1.01. The consensus mark for its revenues stands at $937.5 million. The company carries a Zacks Rank #2.


+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities

In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.

Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.

Click here to download this report FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

PerkinElmer, Inc. (PKI): Free Stock Analysis Report

AMN Healthcare Services (NASDAQ:HCSG) Inc (AMN): Free Stock Analysis Report

Catalent, Inc. (CTLT): Free Stock Analysis Report

Encompass Health Corporation (EHC): Free Stock Analysis Report

To read this article on Zacks.com click here.
PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates
 

Related Articles

PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email